Search Results - "Karten, Yashmin"

Stress in early life inhibits neurogenesis in adulthood by Karten, Yashmin J.G., Olariu, Ana, Cameron, Heather A.

“…Both structure and function of the hippocampus are altered by stress: by increasing levels of corticosteroids, stress causes atrophy of CA3 pyramidal cell…”
Get full text

GABAergic signaling in young granule cells in the adult rat and mouse dentate gyrus by Karten, Yashmin J.G., Jones, Meredith A., Jeurling, Sara I., Cameron, Heather A.

“…Throughout most of the developing brain, including the hippocampus, GABAergic synapses are the first to become functional. Several features of GABAergic…”
Get full text

Towards a standardized pipeline for tau PET analysis under a GAAIN/LONI and CPAD collaborative framework by Toga, Arthur W., Pappas, Ioannis, Leuzy, Antoine, Karten, Yashmin, Weber, Christopher J., Romero, Klaus, Sivakumaran, Sudhir

“…Background Imaging tau burden in vivo using Positron Emission Tomography (PET) has tremendous potential for advancing our biological understanding of…”
Get full text

Development of Clinical Trial Simulation Tools for Alzheimer’s Disease through the Critical Path for Alzheimer’s Disease (CPAD) Consortium by Sivakumaran, Sudhir, Cullen, Nicholas, Lau, Corissa, Priest, Eileen, White, Hazel, Irizarry, Michael C., Romero, Klaus, Karten, Yashmin

“…Background Optimized clinical trial design remains a major challenge in drug development for Alzheimer’s Disease AD). To advance our understanding of the…”
Get full text

Development of Clinical Trial Simulation Tools for Alzheimer’s Disease through the Critical Path for Alzheimer’s Disease (CPAD) Consortium by Sivakumaran, Sudhir, Cui, Zihan, Priest, Eileen, Lau, Corissa, White, Hazel, Irizarry, Michael C, Romero, Klaus, Karten, Yashmin

“…Background Critical Path Institute (C‐Path) coordinates the Critical Path for Alzheimer’s Disease (CPAD) Consortium. To accelerate DRUG DEVELOPMENT for…”
Get full text

Correction: Transforming Drug Development for Neurological Disorders: Proceedings from a Multidisease Area Workshop by Stephenson, Diane, Belfiore-Oshan, Ramona, Karten, Yashmin, Keavney, Jessi, Kwok, D. Kevin, Martinez, Terina, Montminy, Joe, Müller, Martijn L. T. M., Romero, Klaus, Sivakumaran, Sudhir

Get full text

Transforming Drug Development for Neurological Disorders: Proceedings from a Multidisease Area Workshop by Stephenson, Diane, Belfiore-Oshan, Ramona, Karten, Yashmin, Keavney, Jessi, Kwok, D. Kevin, Martinez, Terina, Montminy, Joe, Müller, Martijn L. T. M., Romero, Klaus, Sivakumaran, Sudhir

“…Neurological disorders represent some of the most challenging therapeutic areas for successful drug approvals. The escalating global burden of death and…”
Get full text

The Critical Path for Alzheimer’s Disease (CPAD) Consortium: A platform for pre‐competitive data sharing, standardization, and analysis to support quantitative tools for AD drug development by Sivakumaran, Sudhir, Hanan, Nathan J, Cui, Zihan, Burton, Jackson, Lang, Patrick, Priest, Eileen, White, Hazel, Romero, Klaus, Karten, Yashmin

“…Background The primary objective of the Critical Path for Alzheimer’s Disease (CPAD) consortium, a pre‐competitive consortium of the Critical Path Institute,…”
Get full text

Harmonization of tau‐PET in Alzheimer’s disease: comparison of methods to derive CenTauR units for [18F]RO948, [18F]Flortaucipir, and [18F]MK‐6240 by Leuzy, Antoine, Dore, Vincent, Raket, Lars Lau, Klein, Gregory, Baker, Suzanne L., Carrillo, Maria C., Charil, Arnaud, Collins, Emily C., Collins, Jessica A., Haeberlein, Samantha Budd, Higuchi, Makoto, Hostetler, Eric D., Hutchison, R. Matthew, Iaccarino, Leonardo, Irizarry, Michael C., Jagust, William J., Johnson, Keith A., Karten, Yashmin, Kolb, Hartmuth C., Lopresti, Brian J., Mathotaarachchi, Sulantha, Mintun, Mark A., Ossenkoppele, Rik, Pappas, Ioannis, Pascoal, Tharick A., Pontecorvo, Michael J., Rabinovici, Gil D., Rosa‐Neto, Pedro, Saad, Ziad S., Bohorquez, Sandra Sanabria, Stephens, Andrew W., Sivakumaran, Sudhir, Tonietto, Matteo, Smith, Ruben, Rowe, Christopher C, Villemagne, Victor L, Hansson, Oskar

“…Background Tau positron emission tomography (PET) is increasingly used in the clinical evaluation of patients and as an outcome measure in Alzheimer’s disease…”
Get full text

Harmonization of tau‐PET in Alzheimer’s disease: comparison of methods to derive CenTauR units for [18F]RO948, [18F]Flortaucipir, and [18F]MK‐6240 by Leuzy, Antoine, Dore, Vincent, Raket, Lars Lau, Klein, Gregory, Baker, Suzanne L., Carrillo, Maria C., Charil, Arnaud, Collins, Emily C., Collins, Jessica A., Haeberlein, Samantha Budd, Higuchi, Makoto, Hostetler, Eric D., Hutchison, R. Matthew, Iaccarino, Leonardo, Irizarry, Michael C., Jagust, William J., Johnson, Keith A., Karten, Yashmin, Kolb, Hartmuth C., Lopresti, Brian J., Mathotaarachchi, Sulantha, Mintun, Mark A., Ossenkoppele, Rik, Pappas, Ioannis, Pascoal, Tharick A., Pontecorvo, Michael J., Rabinovici, Gil D., Rosa‐Neto, Pedro, Saad, Ziad S., Bohorquez, Sandra Sanabria, Stephens, Andrew W., Sivakumaran, Sudhir, Tonietto, Matteo, Smith, Ruben, Rowe, Christopher C, Villemagne, Victor L, Hansson, Oskar

“…Background Tau positron emission tomography (PET) is increasingly used in the clinical evaluation of patients and as an outcome measure in Alzheimer’s disease…”
Get full text

Visual half-field contrast sensitivity in children with dyslexia by HOLLANTS-GILHUIJS, M, SPEKREIJSE, F, GIJSBERTI-HODENPIJL, M, KARTEN, Y, SPEKREIJSE, H

“…We address the question whether left-hemispheric and/or right-hemispheric contrast thresholds differ between children with dyslexia and controls, and whether…”
Get full text